Related Experiment Video

Updated: Apr 26, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.7K

The need to define treatment goals for systemic lupus erythematosus

Kate Franklyn1, Alberta Hoi1, Mandana Nikpour2

  • 1Monash University School of Clinical Sciences, Monash Medical Centre, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia.

Nature Reviews. Rheumatology
|July 23, 2014
PubMed

Insights

Systemic lupus erythematosus (SLE) has high mortality despite available treatments. This review explores the potential benefits, challenges, and strategies for implementing a

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Medicine

Background:

  • Systemic lupus erythematosus (SLE) is associated with high mortality rates.
  • Current therapies require optimization pending new treatments.
  • A 'treat-to-target' approach has improved outcomes in other autoimmune diseases like rheumatoid arthritis.

Purpose of the Study:

  • To explore the potential benefits of defining treatment targets for SLE.
  • To identify obstacles hindering the development of a treat-to-target strategy in SLE.
  • To discuss potential strategies for establishing treatment targets in SLE management.

Main Methods:

  • Literature review and synthesis of existing research on SLE treatment and targets.
  • Analysis of the heterogeneity of SLE and challenges in measuring disease activity.
  • Discussion of strategies for developing a consensus on SLE treatment targets.

Main Results:

  • Implementing a treat-to-target approach in SLE could improve patient outcomes.
  • SLE's heterogeneity and lack of standardized outcome measures impede target development.
  • Identifying and agreeing upon specific, measurable targets is crucial for SLE management.

Conclusions:

  • A treat-to-target strategy holds promise for improving SLE outcomes.
  • Overcoming obstacles related to SLE heterogeneity and measurement is essential.
  • Developing consensus and strategies for treatment targets is a critical next step for SLE therapy.

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.6K
Murine Bilateral Renal Lymphadenectomy06:20

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

211

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.3K
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
546
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
407
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
699
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
539
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
719